Filing Flows › Biodesix (BDSX) › Diagnostic Tests revenue
Biodesix (BDSX) Diagnostic Tests revenue by quarter
Biodesix's Diagnostic Tests revenue was $23.1M in Q3 2026 (third quarter 2026), -9% from Q2 2026. Over the last 7 quarters it ranged from $16.3M (Q1 2025) to $25.3M (Q2 2026).
| Quarter | Diagnostic Tests revenue | Q/Q | Y/Y |
|---|---|---|---|
| Q3 2026 | $23.1M | -9% | +16% |
| Q2 2026 | $25.3M | +14% | +42% |
| Q1 2026 | $22.3M | -11% | +37% |
| Q4 2025 | $25.1M | +27% | — |
| Q3 2025 | $19.8M | +11% | — |
| Q2 2025 | $17.9M | +10% | — |
| Q1 2025 | $16.3M | — | — |
Q3 2026 at a glance
Biodesix, Q3 2026: revenue $24.0M (+10% year over year), operating margin -25.4%, net loss $8.0M, operating cash flow −$7.2M. The chart follows the revenue to costs, profit and cash.
Questions
What is Biodesix's Diagnostic Tests revenue?
Biodesix's Diagnostic Tests revenue was $23.1M in Q3 2026 (third quarter 2026), -9% from Q2 2026.
How has Biodesix's Diagnostic Tests revenue changed?
Over the last 7 quarters it ranged from $16.3M (Q1 2025) to $25.3M (Q2 2026).